Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.